Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 11/20 | 0.63 |
| ▸ | PGR | P06401 | 3/20 | 0.46 |
| ▸ | ACVR1 | Q04771 | 4/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | BPTF | Q12830 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3228629 | 0.88 | NR3C1 (0.72) | NR3C1PGR | |
| SCHEMBL3233100 | 0.85 | NR3C1 (0.58) | NR3C1PGRACVR1CREBBPBPTF | |
| SCHEMBL3231133 | 0.84 | NR3C1 (0.86) | NR3C1PGRACVR1BPTFRORC | |
| SCHEMBL3219408 | 0.81 | NR3C1 (0.55) | NR3C1PGRACVR1BPTF | |
| SCHEMBL3228490 | 0.78 | NR3C1 (0.58) | NR3C1PGRACVR1BPTF | |
| SCHEMBL3233010 | 0.77 | NR3C1 (1.00) | NR3C1PGRACVR1RORC | |
| SCHEMBL3233363 | 0.77 | NR3C1 (0.73) | NR3C1PGRACVR1 | |
| SCHEMBL3228426 | 0.73 | NR3C1 (0.72) | NR3C1PGR | |
| SCHEMBL3234048 | 0.73 | NR3C1 (0.67) | NR3C1PGR | |
| SCHEMBL3236933 | 0.73 | NR3C1 (0.67) | NR3C1PGRACVR1BPTF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2116538-B1 | CONDENSED TETRAHYDROQUINOLINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-03-27 | — | — | EP | disclosed |
| US-8367695-B2 | Condensed tetrahydroquinoline derivative and use thereof for medical purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20100063055-A1 | CONDENSED TETRAHYDROQUINOLINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-03-11 | — | — | US | disclosed |
| EP-2116538-A1 | CONDENSED TETRAHYDROQUINOLINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063055-A1 | CONDENSED TETRAHYDROQUINOLINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | NR3C2, MC2R, NR5A1 | NR3C1 4/4885PGR 11/4885ACVR1 3784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.